fashion -WSS

fashion

author：fashion 2025-09-27 13:10:34 - browse：93585

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： General Catalyst, Summa Health deal will turn on physician buy

entertainment

WSS

Cognito secures funding to test medical device for Alzheimer's

Virtual repurposing can help discover new uses for existing drugs

SAMSHA loosens regulations on methadone treatment centers

Commercial surrogacy can be ethical, despite pope’s claims

Doctor of U.S. President Joe Biden says he is fit for duty

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Wikipedia

fashion

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Heart attack and stroke risk calculators need revising

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

The cancer drug shortage isn’t new — and neither are the solutions

New Ultima Genomics DNA sequencer can read genome for $100

Wildfire smoke exposes gaps in outdoor worker protections

A $475,000 price tag for a new cancer drug: crazy or meh?

Continuity nursing helped my family in our darkest PICU moments

'Vaccine

hotspot

What we need to know about Arena Bioworks

CDC advisory group OKs chikungunya vaccine

Do digital therapeutics have a future in medicine?

STAT Madness 2024: Meet the contenders

Doctor of U.S. President Joe Biden says he is fit for duty

Cholera vaccine supplies dangerously low, outbreaks surging

hotspot

entertainment

entertainment

focus